In this Q&A, Dr. Saad Usmani, Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, answers questions from patients about what their diagnosis means today, how treatment decisions are made, and how new breakthroughs are changing what is possible in 2026 and beyond. Learn more about CAR-T therapies, bispecific antibodies, and precision-based drug combinations that are rewriting what remission and survival look like.

Neither Outcomes4Me nor any participants in or contributors to any webinar, article or content endorses or recommends any products or services. Consult your physician regarding any treatment or therapy.